×
About 2,048 results

ALLMedicine™ Lennox-gastaut Syndrome Center

Research & Reviews  302 results

Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome.
https://doi.org/10.1016/j.eplepsyres.2021.106813
Epilepsy Research; Asadi-Pooya AA, Bazrafshan M et. al.

Nov 20th, 2021 - The aim of the current study was to investigate the long-term outcome in a large cohort of patients with Lennox-Gastaut syndrome (LGS). This was a longitudinal study (a retrospective database review with a telephone follow-up interview). All patie...

Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Synd...
https://doi.org/10.1016/j.clinthera.2021.09.017
Clinical Therapeutics; Lo SH, Lloyd A et. al.

Nov 15th, 2021 - Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are rare, treatment-resistant forms of epilepsy characterized by childhood onset of seizures. Cost-effectiveness analysis for new antiseizure medications typically requires health state utilit...

Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Chi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551105
CNS Drugs; Klotz KA, Grob D et. al.

Oct 24th, 2021 - Cannabidiol has been shown to be effective in seizure reduction in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis. However, very little is known about its potential to reduce interictal epileptiform activity and imp...

Epidiolex plus THC lowers seizures in pediatric epilepsy
https://www.mdedge.com/neurology/article/247341/epilepsy-seizures/epidiolex-plus-thc-lowers-seizures-pediatric-epilepsy
Randy Dotinga

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

Severe autonomic nervous system imbalance in Lennox-Gastaut syndrome patients demonstra...
https://doi.org/10.1016/j.eplepsyres.2021.106783
Epilepsy Research; Hödl S, Olbert E et. al.

Oct 10th, 2021 - Patients diagnosed with Lennox Gastaut syndrome (LGS), an epileptic encephalopathy characterized by usually drug resistant generalized and focal seizures, are often considered as candidates for vagus nerve stimulation (VNS). Recent research shows ...

see more →

Drugs  405 results see all →

Clinicaltrials.gov  12 results

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
https://clinicaltrials.gov/ct2/show/NCT03731715

Oct 7th, 2021 - A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer a...

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).
https://clinicaltrials.gov/ct2/show/NCT04721691

Jul 16th, 2021 - This study attempts to view the effect of Epidiolex on subjects with Electrical Status Epilepticus of Sleep (ESES). ESES can cause various types of seizures which can fluctuate during sleep. Similar studies have been conducted with Epidiolex with ...

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
https://clinicaltrials.gov/ct2/show/NCT03355209

Jun 18th, 2021 - This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome ...

GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes
https://clinicaltrials.gov/ct2/show/NCT02224573

Oct 14th, 2020 - This is a multi-center, open-label extension study for participants with Dravet syndrome or Lennox-Gastaut syndrome who have previously participated in double-blind, placebo-controlled clinical studies of GWP42003-P (Core Studies). The first parti...

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
https://clinicaltrials.gov/ct2/show/NCT01405053

Aug 6th, 2019 - This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.

see more →

News  100 results

Epidiolex plus THC lowers seizures in pediatric epilepsy
https://www.mdedge.com/neurology/article/247341/epilepsy-seizures/epidiolex-plus-thc-lowers-seizures-pediatric-epilepsy
Randy Dotinga

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

CBD Gel a Promising Adjunct for Kids With Severe Epilepsy
https://www.medscape.com/viewarticle/958889

Sep 16th, 2021 - Topical cannabidiol (CBD) gel, added to antiseizure medication, may help reduce seizures and improve quality of life in children with developmental and epileptic encephalopathies, according to the results of a nonrandomized controlled trial. Devel...

An Update on New Epilepsy Medications
https://www.medscape.com/viewarticle/949554

Apr 20th, 2021 - At the ongoing Academy of Neurology 2021 Annual Meeting, being held virtually on April 17-22, Joseph Sirven, MD, professor of neurology at the Mayo Clinic in Jacksonville, Florida, led an epilepsy course updating viewers on new epilepsy medication...

Cannabidiol Cleared for Tuberous Sclerosis Complex in Europe
https://www.medscape.com/viewarticle/949596

Apr 20th, 2021 - The European Commission (EC) has approved cannabidiol (Epidyolex) oral solution as adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older. It's the third indication for the drug in Euro...

Cannabinoids 'Worth a Try' for Agitation in Alzheimer's
https://www.medscape.com/viewarticle/945163

Feb 2nd, 2021 - Tetrahydrocannabinol (THC), the psychoactive agent in cannabinoids, may provide an alternative to off-label use of antipsychotics and other medications to manage agitation in patients with Alzheimer's disease (AD), a new clinical review suggests. ...

see more →